RT Journal Article
T1 Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
A1 Ibanez-Costa, Alejandro
A1 Rivero-Cortes, Esther
A1 Vazquez-Borrego, Mari C.
A1 Gahete, Manuel D.
A1 Jimenez-Reina, Luis
A1 Venegas-Moreno, Eva
A1 de la Riva, Andres
A1 Angel Arraez, Miguel
A1 Gonzalez-Molero, Inmaculada
A1 Schmid, Herbert A.
A1 Maraver-Selfa, Silvia
A1 Gavilan-Villarejo, Inmaculada
A1 Antonio Garcia-Arnes, Juan
A1 Japon, Miguel A.
A1 Soto-Moreno, Alfonso
A1 Galvez, Maria A.
A1 Luque, Raul M.
A1 Castano, Justo P.
K1 Growth-hormone
K1 Receptor subtypes
K1 Quantitative-analysis
K1 Aggressive features
K1 Medical-treatment
K1 Cushings-disease
K1 Acth release
K1 Adenomas
AB Somatostatin analogs (SSA) are the mainstay of pharmacological treatment for pituitary adenomas. However, some patients escape from therapy with octreotide, a somatostatin receptor 2 (sst2)-preferring SSA, and pasireotide, a novel multi-sst-preferring SSA, may help to overcome this problem. It has been proposed that correspondence between sst1-sst5 expression pattern and SSA-binding profile could predict patient's response. To explore the cellular/molecular features associated with octreotide/pasireotide response, we performed a parallel comparison of their in vitro effects, evaluating sst1-sst5 expression, intracellular Ca2+ signaling ([Ca2+](i)), hormone secretion and cell viability, in a series of 85 pituitary samples. Somatotropinomas expressed sst5>sst2, yet octreotide reduced [Ca2+](i) more efficiently than pasireotide, while both SSA similarly decreased growth hormone release/expression and viability. Corticotropinomas predominantly expressed sst5, but displayed limited response to pasireotide, while octreotide reduced functional endpoints. Non-functioning adenomas preferentially expressed sst3 but, surprisingly, both SSA increased cell viability. Prolactinomas mainly expressed sst1 but were virtually unresponsive to SSA. Finally, both SSA decreased [Ca2+](i) in normal pituitaries. In conclusion, both SSA act in vitro on pituitary adenomas exerting both similar and distinct effects; however, no evident correspondence was found with the sst1-sst5 profile. Thus, it seems plausible that additional factors, besides the simple abundance of a given sst, critically influence the SSA response.
PB BioScientifica
SN 0022-0795
YR 2016
FD 2016-09-01
LK http://hdl.handle.net/10668/19187
UL http://hdl.handle.net/10668/19187
LA en
NO Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol. 2016 Nov;231(2):135-145
DS RISalud
RD Apr 5, 2025